Pharma changing its approach to drug trials; Infinity Pharmaceuticals bounces back;

 @FierceBiotech: Pfizer to lop off Asian research unit amid major R&D downsizing. Story | Follow @FierceBiotech

 @RyanMFierce: Troubled biotech Tranzyme mulls potential sale after R&D face plants. More | Follow @RyanMFierce

> Pharma companies are changing their approach to how they conduct drug trials. Story

> Pergamum AB and Cadila Pharmaceuticals have formed a partnership to develop therapies to treat infections. Press release

> Infinity Pharmaceuticals ($INFI) saw a 6-fold rise in market share, from $5.98 a share on its lowest day of 2012, to $35.02 at yesterday's close. Story

> Biotechs are embracing RNA therapeutics. Story

Pharma News

 @FiercePharma: Turns out, Vivus' slow launch of Qsymia may be best plan. News | Follow @FiercePharma

 @EricPFierce: Sun tells Taro shareholders to forget it, cancels $685 million offer for Israeli generic drug player. Report | Follow @EricPFierce

 @AlisonBFierce: Evidence of a link between GSK's Pandemrix and a spike in narcolepsy cases is putting AS03 under intense scrutiny. More | Follow @AlisonBFierce

> Court spoons out good news for Merck investors. Report

> Pfizer cuts some more, closing R&D site in Singapore. Item

Medical Device News

 @FierceMedDev: Ultrasound elastography eyed as cancer Dx method. Report | Follow @FierceMedDev

 @MarkHFierce: India is competing with the larger device companies by launching firms that make cheaper, quality alternatives. News | Follow @MarkHFierce

 @DamianFierce: LabCorp joins the list of diagnostics providers expecting Medicare cuts to take a bite out of 2013 revenue. Story | Follow @DamianFierce

> India's med device outfits beat multinationals on price. News

> Insulet ditches DexCom in diabetes collaboration. Article

And Finally... Who would have thought? A major investor picks hot takeover candidates in biotech--from his own firm's portfolio. Seriously. Story

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.